Trade Mark Journal No.2026/040 2 October 2026

UK00004446067 16 September 2026 (5)

RETAHVERA

Class 5: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorder, alopecia, Alzheimer’s disease, asthma, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, cancer, cardiovascular disease, central nervous system diseases and disorders, Crohn’s disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hearing loss, heart failure, infectious diseases, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, obstructive sleep apnea, opioid use disorder, osteoarthritis, pain, Parkinson’s disease, psoriasis, psoriatic arthritis, pulmonary diseases, retinal disease, rheumatoid arthritis, tobacco use disorder, ulcerative colitis, vascular diseases and vision loss; pharmaceutical preparations for weight management; vaccines for human use.

Eli Lilly and Company

Representative: Page, White & Farrer Limited